Quote | Lumos Pharma Inc. (NASDAQ:LUMO)
Last: | $2.20 |
---|---|
Change Percent: | -3.08% |
Open: | $2.24 |
Close: | $2.27 |
High: | $2.275 |
Low: | $2.2 |
Volume: | 2,183 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Lumos Pharma Inc. (NASDAQ:LUMO)
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Message Board Posts | Lumos Pharma Inc. (NASDAQ:LUMO)
Subject | By | Source | When |
---|---|---|---|
I recently bought shares based mainly on the | fishhunter | investorshub | 09/19/2021 8:53:02 PM |
whytestocks: $NLNK News Article - NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERV | whytestocks | investorshangout | 12/20/2019 3:30:42 PM |
whytestocks: $NLNK News Article - NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommen | whytestocks | investorshangout | 10/21/2019 8:35:44 PM |
whytestocks: $NLNK News Article - Captivating Stock- NewLink Genetics Corporation (NASDAQ:NLNK) | whytestocks | investorshangout | 08/21/2019 8:45:40 PM |
whytestocks: $NLNK News Article - NewLink Genetics Provides Corporate Update and Reports Second Quar | whytestocks | investorshangout | 07/30/2019 7:25:40 PM |
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...